Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) FCF Margin (2020 - 2025)

Historic FCF Margin for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to 60.7%.

  • Vivos Therapeutics' FCF Margin rose 530900.0% to 60.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.79%, marking a year-over-year increase of 11500.0%. This contributed to the annual value of 88.27% for FY2024, which is 41100.0% up from last year.
  • Vivos Therapeutics' FCF Margin amounted to 60.7% in Q3 2025, which was up 530900.0% from 111.81% recorded in Q2 2025.
  • Vivos Therapeutics' FCF Margin's 5-year high stood at 60.7% during Q3 2025, with a 5-year trough of 170.69% in Q1 2022.
  • In the last 5 years, Vivos Therapeutics' FCF Margin had a median value of 97.98% in 2021 and averaged 103.73%.
  • In the last 5 years, Vivos Therapeutics' FCF Margin plummeted by -1068800bps in 2021 and then skyrocketed by 727400bps in 2023.
  • Quarter analysis of 5 years shows Vivos Therapeutics' FCF Margin stood at 102.5% in 2021, then rose by 21bps to 81.01% in 2022, then decreased by -11bps to 89.62% in 2023, then rose by 8bps to 82.88% in 2024, then grew by 27bps to 60.7% in 2025.
  • Its FCF Margin was 60.7% in Q3 2025, compared to 111.81% in Q2 2025 and 130.04% in Q1 2025.